Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051996 · ClinicalTrials.gov registry record · Phase 2
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04051996 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants.
The verdict
NCT04051996, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either refuse or are ineligible for intensive therapy.
Interventions
- DRUG Decitabine
- DRUG Glasdegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2020-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04051996
The ClinicalTrials.gov registry entry for NCT04051996 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT04051996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04051996 about?
NCT04051996 is a clinical study titled "GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia". This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either re...
What is the current status of trial NCT04051996?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-12-06. Estimated completion is 2020-06-09.
What interventions are being tested in trial NCT04051996?
The interventions under investigation include: Decitabine (DRUG), Glasdegib (DRUG).
Who is sponsoring clinical trial NCT04051996?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.